Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin plus interpersonal sensorimotor synchronization therapy for social attunement in autism
2023-505253-41-01Phase 3Authorised
- Sponsor
- UZ Leuven
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of oxytocin and sodium chloride in Autism Spectrum Disorder (ASD) (2 arms), sponsored by UZ Leuven. Primary endpoint: Change from baseline in dyadic attunement. Planned start Jun 2024; status: authorised.
02
Drugs
oxytocinsodium chloride
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2023-505253-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505253-41-01.